DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Information source: Gachon University Gil Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Eisenmenger's Syndrome

Phase: N/A

Status: Completed

Sponsored by: Gachon University Gil Medical Center

Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Clinical Details

Official title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Study design: Observational Model: Case-Only, Time Perspective: Retrospective

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria:

Locations and Contacts

Additional Information

Starting date: September 2007
Last updated: January 25, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017